RET and medullary thyroid gland carcinoma: Overall, selpercatinib was well tolerated with durable efficacy, and subsequently received accelerated approval based on these initial data from the first 144 NSCLC patients, 143 MTC patients and 19 RET fusion–positive thyroid cancer patients in the LIBRETTO-001 trial [15,16].